Two biotech start-ups focusing on programmable cell death have merged. The move will "broaden IDUN's technology base," increase research staff and "provide sufficient financing to weather the harsh conditions in the current marketplace," La Jolla, Calif.- based IDUN says. The new company, which just raised $7.2 mil. in venture capital from Accel Partners and Venrock Associates, will retain the IDUN name and be based in La Jolla
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth